论文部分内容阅读
目的:分析不同剂量氨溴索口服液对糖尿病伴社区获得性肺炎患者的临床疗效。方法:选取2013年1月—2014年3月间收治的糖尿病伴社区获得性肺炎患者75例,按照数字表法将其分为对照组37例和观察组38例;两组患者均给予常规对症治疗,对照组患者在此基础上给予常规剂量(1支,tid)氨溴索口服液治疗,观察组患者在常规对症治疗基础上给予双倍剂量(1支,tid)氨溴索口服液治疗,分析两组患者治疗后的总有效率和治疗前后症状评分值及不良反应的发生情况。结果:观察组患者治疗后症状评分值明显低于对照组(P<0.05);观察组患者治疗的总有效率为97.37%高于对照组为78.38%(P<0.05);观察组患者不良反应的发生情况与对照组患者相比,其差异无统计学意义(P>0.05)。结论:高剂量氨溴索口服液用于治疗糖尿病伴社区获得性肺炎患者的疗效果较显著,能有效提升治疗的总有效率。
Objective: To analyze the clinical efficacy of different doses of ambroxol orally on diabetic patients with community-acquired pneumonia. Methods: Seventy-five patients with diabetes mellitus and community-acquired pneumonia who were admitted to our hospital from January 2013 to March 2014 were divided into control group (n = 37) and observation group (n = 38) according to digital table method. Both groups were given conventional symptomatic The patients in the control group were treated with ambroxol orally at a conventional dose (1 tid), and the patients in the observation group were given double-dose (1 tid) ambroxol oral liquid on the basis of routine symptomatic treatment , Analysis of two groups of patients after treatment, the total effective rate and symptom scores before and after treatment and the occurrence of adverse reactions. Results: The symptom score of the observation group was significantly lower than that of the control group (P <0.05). The total effective rate of the observation group was 97.37%, 78.38% (P <0.05) of the control group. The adverse reactions of the observation group Compared with the control group, the difference was not statistically significant (P> 0.05). Conclusion: The high dose of ambroxol oral solution for the treatment of diabetes patients with community-acquired pneumonia treatment effect is more significant, can effectively improve the overall efficiency of treatment.